Proprotein convertase subtilisin/kexin 9 inhibitors: An emerging lipid-lowering therapy?

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 20, Issue 2, 2015, Pages 157-168

  Dragan, Simona ^a   Serban, Maria Corina ^a   Banach, Maciej ^b  

^a VICTOR BABES UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

low density lipoprotein receptor; PCSK9; proprotein convertase subtilisin kexin 9; statins

Indexed keywords

ALIROCUMAB; ALN PCS 02; ANTILIPEMIC AGENT; ANTISENSE OLIGONUCLEOTIDE; APOLIPOPROTEIN B100; APOLIPOPROTEIN C; BOCOCIZUMAB; EVOLOCUMAB; HYPOCHOLESTEROLEMIC AGENT; IB 20; ISIS 394814; J 10; J 16; J 17; LGT 209; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; LY 3015014; MONOCLONAL ANTIBODY; PEGDINETANIB; PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9; PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9 INHIBITOR; RG 7652; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR; SPC 4061; SPC 5001; SPC 5011; SX PCSK 9; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN; PCSK9 PROTEIN, HUMAN;

CATALYSIS; EMBASE; GENE SILENCING; HUMAN; HYPERCHOLESTEROLEMIA; LIPID METABOLISM; MEDLINE; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS INHIBITION; REVIEW; RNA INTERFERENCE; SCOPUS; ANTAGONISTS AND INHIBITORS; BLOOD; CLINICAL TRIAL (TOPIC); PHYSIOLOGY;

ANTIBODIES, MONOCLONAL; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; CLINICAL TRIALS AS TOPIC; HUMANS; LIPID METABOLISM; OLIGONUCLEOTIDES, ANTISENSE; PROPROTEIN CONVERTASES; RECEPTORS, LDL; SERINE ENDOPEPTIDASES;

EID: 84922593883     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248414539562     Document Type: Review

References (108)

1. Goldberg AC, Hopkins PN, Toth PP, et al. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the national lipid association expert panel on familial hypercholesterolemia. J Clin Lipidol. 2011 ; 5 (3). 133-140
2. Rynkiewicz A, Cybulska B, Banach M, et al. Management of familial heterozygous hypercholesterolemia: position paper of the Polish Lipid Expert Forum. J Clin Lipidol. 2013 ; 7 (3). 217-221
3. Goldberg AC, Robinson JG, Cromwell WC, Ross JL, Ziajka PE. Future issues, public policy, and public awareness of familial hypercholesterolemias: recommendations from the national lipid association expert panel on familial hypercholesterolemia. J Clin Lipidol. 2011 ; 5 (3 suppl). S46 - S51
4. Myliwiec M, Walczak M, Malecka-Tendera E, et al. Management of familial hypercholesterolemia in children and adolescents. Position paper of the Polish Lipid Expert Forum. J Clin Lipidol. 2014 ; 8 (2). 173-180
5. Nordestgaard BG, Chapman MJ, Humphries SE, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European atherosclerosis society. Eur Heart J. 2013 ; 34 (45). 3478-3490a
6. Farnier M. The role of proprotein convertase subtilisin/kexin type 9 in hyperlipidemia: focus on therapeutic implications. Am J Cardiovasc Drugs. 2011 ; 11 (3). 145-152
7. Barylski M, Malyszko J, Rysz J, Myliwiec M, Banach M. Lipids, blood pressure, kidney - what was new in 2011?. Arch Med Sci. 2011 ; 7 (6). 1055-1066
8. Mark L, Paragh G, Karadi I, Reiber I, Pados G, Kiss Z. An attempt to make lipid-lowering therapy more effective in Hungary. The results of MULTI GAP 2010 and the PLUS Program. Arch Med Sci. 2011 ; 7 (5). 760-766
9. Rizzo M, Barylski M, Rizvi AA, et al. Combined dyslipidemia: should the focus be LDL cholesterol or atherogenic dyslipidemia?. Curr Pharm Des. 2013 ; 19 (21). 3858-3868
10. Rizzo M, Banach M, Montalto G, Mikhailidis DP. Lipid-lowering therapies and achievement of LDL-cholesterol targets. Arch Med Sci. 2012 ; 8 (4). 598-600
11. Katsiki N, Mikhailidis DP, Banach M. Effects of statin treatment on endothelial function, oxidative stress and inflammation in patients with arterial hypertension and normal cholesterol levels. J Hypertens. 2011 ; 29 (12). 2493-2494
12. Katsiki N, Mikhailidis DP, Athyros VG, Hatzitolios AI, Karagiannis A, Banach M. Are we getting to lipid targets in real life?. Arch Med Sci. 2010 ; 6 (5). 639-641
13. Banach M, Mikhailidis DP, Kjeldsen SE, Rysz J. Time for new indications for statins?. Med Sci Monit. 2009 ; 15 (12). MS1 - MS5
14. Pijlman AH, Huijgen R, Verhagen SN. Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in the Netherlands. Atherosclerosis. 2010 ; 209 (1). 189-194
15. Kotseva K, Wood D, De Backer G, et al. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil. 2009 ; 16 (2). 121-137
16. Seidah NG, Benjannet S, Wickham L, et al. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci USA. 2003 ; 100 (3). 928-933
17. Toth PP The Year in Lipid Disorders. 1 st ed. Oxford, United Kingdom: Clinical Pub Serv; 2010:332. Oxford, United Kingdom: Clinical Pub Serv ; 2010: 332.
18. Ferri N, Tibolla G, Pirillo A, et al. Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels. Atherosclerosis. 2012 ; 220 (2). 381-386
19. Wooten CJ, Adcock AF, Agina-Obu DI, Lopez D. Having excess levels of PCSK9 is not sufficient to induce complex formation between PCSK9 and the LDL receptor. Arch Biochem Biophys. 2014 ; 545: 124-132
20. Banach M, Rizzo M, Obradovic M, et al. PCSK9 inhibition - a novel mechanism to treat lipid disorders?. Curr Pharm Des. 2013 ; 19 (21). 3869-3877
21. Attie AD, Seidah NG. Dual regulation of the LDL receptor - some clarity and new questions. Cell Metab. 2005 ; 1 (5). 290-292
22. Abifadel M, Varret M, Rabès JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003 ; 34 (2). 154-156
23. Wu NQ, Guo YL, Xu RX, et al. Acute myocardial infarction in an 8-year old male child with homozygous familiar hypercholesterolemia: laboratory findings and response to lipid-lowering drugs. Clin Lab. 2013 ; 59 (7-8). 901-907
24. Cohen JC, Boerwinkle E, Mosley TH, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006 ; 354 (12). 1264-1272
25. Mbikay M, Sirois F, Mayne J, et al. PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities. FEBS Lett. 2010 ; 584 (4). 701-706
26. Seidah NG, Sadr MS, Chrétien M, Mbikay M. The multifaceted proprotein convertases: their unique, redundant, complementary, and opposite functions. J Biol Chem. 2013 ; 288 (30). 21473-21481
27. Roubtsova A, Munkonda MN, Awan Z, et al. Circulating proprotein convertase subtilisin/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue. Arterioscler Thromb Vasc Biol. 2011 ; 31 (4). 785-791
28. Zaid A, Roubtsova A, Essalmani R, et al. Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration. Hepatology. 2008 ; 48 (2). 646-654
29. Dubuc G, Tremblay M, Paré G, et al. A new method for measurement of total plasma PCSK9: clinical applications. J Lipid Res. 2010 ; 51 (1). 140-149
30. Nassoury N, Blasiole DA, Tebon Oler A, et al. The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR. Traffic. 2007 ; 8 (6). 718-732
31. Davignon J, Dubuc G. Statins and ezetimibe modulate plasma proprotein convertase subtilisin kexin-9 (PCSK9) levels. Trans Am Clin Climatol Assoc. 2009 ; 120: 163-173
32. Alborn WE, Cao G, Careskey HE, et al. Serum proprotein convertase subtilisin kexin type 9 is correlated directly with serum LDL cholesterol. Clin Chem. 2007 ; 53 (10). 1814-1819
33. Baass A, Dubuc G, Tremblay M, et al. Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents. Clin Chem. 2009 ; 55 (9). 1637-1645
34. Dubuc G, Chamberland A, Wassef H, et al. Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2004 ; 24 (8). 1454-1459
35. Jung D, Kullak-Ublick GA. Hepatocyte nuclear factor 1 alpha: a key mediator of the effect of bile acids on gene expression. Hepatology. 2003 ; 37 (3). 622-631
36. Li H, Dong B, Park SW, Lee HS, Chen W, Liu J. Hepatocyte nuclear factor 1alpha plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine. J Biol Chem. 2009 ; 284 (42). 28885-28895
37. Welder G, Zineh I, Pacanowski MA, Troutt JS, Cao G, Konrad RJ. High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol. J Lipid Res. 2010 ; 51 (9). 2714-2721
38. Huijgen R, Boekholdt SM, Arsenault BJ, et al. Plasma PCSK9 levels and clinical outcomes in the TNT (Treating to New Targets) trial: a nested case-control study. J Am Coll Cardiol. 2012 ; 59 (20). 1778-1784
39. Maxwell KN, Breslow JL. Antibodies to PCSK9: a superior way to lower LDL cholesterol?. Circ Res. 2012 ; 111 (3). 274-247
40. Wierzbicki AS, Hardman TC, Viljoen A. Inhibition of pre-protein convertase serine kexin-9 (PCSK-9) as a treatment for hyperlipidaemia. Expert Opin Investig Drugs. 2012 ; 21 (5). 667-676
41. Blasiole DA, Davis RA, Attie AD. The physiological and molecular regulation of lipoprotein assembly and secretion. Mol Biosyst. 2007 ; 3 (9). 608-619
42. Mousavi SA, Berge KE, Leren TP. The unique role of proprotein convertase subtilisin/kexin 9 in cholesterol homeostasis. J Intern Med. 2009 ; 266 (6). 507-519
43. Tibolla G, Norata GD, Artali R, Meneghetti F, Catapano AL. Proprotein convertase subtilisin/kexin type 9 (PCSK9): from structure-function relation to therapeutic inhibition. Nutr Metab Cardiovasc Dis. 2011 ; 21 (11). 835-843
44. Ni YG, Condra JH, Orsatti L, et al. A proprotein convertase subtilisin-like/kexin type 9 (PCSK9) C-terminal domain antibody antigen-binding fragment inhibits PCSK9 internalization and restores low density lipoprotein uptake. J Biol Chem. 2010 ; 285 (17). 12882-12891
45. Havel RJ, Hamilton RL. Hepatocytic lipoprotein receptors and intracellular lipoprotein catabolism. Hepatology. 1988 ; 8 (6). 1689-1704
46. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science. 1986 ; 232 (4746). 34-47
47. Steinberg D, Witztum JL. Inhibition of PCSK9: a powerful weapon for achieving ideal LDL cholesterol levels. Proc Natl Acad Sci USA. 2009 ; 106 (24). 9546-9547
48. Maxwell KN, Soccio RE, Duncan EM, Sehayek E, Breslow JL. Novel putative SREBP and LXR target genes identified by microarray analysis in liver of cholesterol-fed mice. J Lipid Res. 2003 ; 44 (11). 2109-2119
49. Huang CC, Fornage M, Lloyd-Jones DM, Wei GS, Boerwinkle E, Liu K. Longitudinal association of PCSK9 sequence variations with low-density lipoprotein cholesterol levels: the coronary artery risk development in young adults study. Circ Cardiovasc Genet. 2009 ; 2 (4). 354-361
50. Park SW, Moon YA, Horton JD. Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver. J Biol Chem. 2004 ; 279 (48). 50630-50638
51. Maxwell KN, Breslow JL. Proprotein convertase subtilisin kexin 9: the third locus implicated in autosomal dominant hypercholesterolemia. Curr Opin Lipidol. 2005 ; 16 (2). 167-172
52. Akram ON, Bernier A, Petrides F, Wong G, Lambert G. Beyond LDL cholesterol, a new role for PCSK9. Arterioscler Thromb Vasc Biol. 2010 ; 30 (7). 1279-1281
53. Horton JD, Cohen JC, Hobbs HH. Molecular biology of PCSK9: its role in LDL metabolism. Trends Biochem Sci. 2007 ; 32 (2). 71-77
54. Lambert G, Charlton F, Rye KA, Piper DE. Molecular basis of PCSK9 function. Atherosclerosis. 2009 ; 203 (1). 1-7
55. Poirier S, Mayer G, Benjannet S, et al. The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2. J Biol Chem. 2008 ; 283 (4). 2363-2372
56. Catapano AL, Papadopoulos N. The safety of therapeutic monoclonal antibodies: implications for cardiovascular disease and targeting the PCSK9 pathway. Atherosclerosis. 2013 ; 228 (1). 18-28
57. Cariou B, Le May C, Costet P. Clinical aspects of PCSK9. Atherosclerosis. 2011 ; 216 (2). 258-265
58. Schiele F, Park J, Redemann N, Luippold G, Nar H. An antibody against the C-terminal domain of PCSK9 lowers LDL cholesterol levels in vivo. J Mol Biol. 2014 ; 426 (4). 843-852
59. Duff CJ, Scott MJ, Kirby IT, Hutchinson SE, Martin SL, Hooper NM. Antibody-mediated disruption of the interaction between PCSK9 and the low-density lipoprotein receptor. Biochem J. 2009 ; 419 (3). 577-584
60. Ni YG, Di Marco S, Condra JH, et al. A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo. J Lipid Res. 2011 ; 52 (1). 78-86
61. Zhang L, McCabe T, Condra JH, et al. An anti-PCSK9 antibody reduces LDL-cholesterol on top of a statin and suppresses hepatocyte SREBP-regulated genes. Int J Biol Sci. 2012 ; 8 (3). 310-327
62. Liang H, Chaparro-Riggers J, Strop P, et al. Proprotein convertase substilisin/kexin type 9 antagonism reduces low-density lipoprotein cholesterol in statin-treated hypercholesterolemic nonhuman primates. J Pharmacol Exp Ther. 2012 ; 340 (2). 228-236
63. Bostrom J, Lee CV, Haber L, Fuh G. Improving antibody binding affinity and specificity for therapeutic development. Methods Mol Biol. 2009 ; 525: 353-376
64. Chaparro-Riggers J, Liang H, DeVay RM, et al. Increasing serum half-life and extending cholesterol lowering in vivo by engineering antibody with pH-sensitive binding to PCSK9. J Biol Chem. 2012 ; 287 (14). 11090-11097
65. Poirier S, Mayer G. The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol. Drug Des Devel Ther. 2013 ; 7: 1135-1148
66. Davies J, Darling R., Allan B. Antibodies to PCSK9 and uses thereof. US patent 20130071405A1. ; ;..
67. Chan JC, Piper DE, Cao Q, et al. A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates. Proc Natl Acad Sci USA. 2009 ; 106 (24). 9820-9825
68. Stein EA, Mellis S, Yancopoulos GD, et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med. 2012 ; 366 (12). 1108-1118
69. Dias CS, Shaywitz AJ, Wasserman SM, et al. Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins. J Am Coll Cardiol. 2012 ; 60 (19). 1888-1898
70. Rue S, Cohen S, Li J, Yowe D. PCSK9 antagonists. US patent 20110142849A1. ; ;..
71. Novartis Pharmaceuticals Safety, pharmacokinetics and pharmacodynamics of LGT209 in healthy volunteers with elevated cholesterol and in hypercholesterolemic patients treated with statins. http://www.clinicaltrials.gov/ct2/show/NCT00265317. http://clinicaltrials.gov/ct2/show/NCT01859455. Accessed September 12, 2013.
72. Sullivan D, Olsson AG, Scott R, et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA. 2012 ; 308 (23). 2497-2506
73. Stein EA, Honarpour N, Wasserman SM, Xu F, Scott R, Raal FJ. Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia. Circulation. 2013 ; 128 (19). 2113-2120
74. Koren MJ, Scott R, Kim JB, et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet. 2012 ; 380 (9858). 1995-2006
75. Hirayama A, Honarpour N, Yoshida M, et al. Effects of evolocumab (AMG 145), a monoclonal antibody to PCSK9, in hypercholesterolemic, statin-treated Japanese patients at high cardiovascular risk. Circ J. 2014 ; 78 (5). 1073-1082
76. Raal F, Scott R, Somaratne R, et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 inhibition in heterozygous familial hypercholesterolemia disorder (RUTHERFORD) randomized trial. Circulation. 2012 ; 126 (20). 2408-2417
77. Desai NR, Giugliano RP, Zhou J, et al. AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of national cholesterol education program-adult treatment panel III low-density lipoprotein cholesterol goals among high-risk patients: an analysis from the LAPLACE-TIMI 57 trial (LDL-C assessment with PCSK9 monoclonal antibody inhibition combined with statin thErapy-thrombolysis in myocardial infarction 57). J Am Coll Cardiol. 2014 ; 63 (5). 430-433
78. Koren MJ, Giugliano RP, Raal FJ, et al. Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial. Circulation. 2014 ; 129 (2). 234-243
79. Mearns B.M. Dyslipidaemia: 1-year results from OSLER trial of anti-PCSK9 monoclonal antibody evolocumab. Nat Rev Cardiol. 2014 ; 11 (2). 63
80. Stein EA, Giugliano RP, Koren MJ, et al. Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials [published online March 4, 2014]. Eur Heart J. 2014 ;:
81. Genentech A phase II study of the safety and efficacy of MPSK3169A in patients with coronary heart disease or high risk of coronary heart disease. http://clinicaltrials.gov/ct2/show/NCT01609140. Accessed May 21, 2014.
82. Koren MJ, Lundqvist P, Bolognese M, et al. Anti-PCSK9 monotherapy for hypercholesterolemia - the MENDEL-2 randomized, controlled phase 3 clinical trial of evolocumab [published online March 25, 2014.]. J Am Coll Cardiol. 2014 ;:
83. Blom DJ, Hala T, Bolognese M, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med. 2014 ; 370 (19). 1809-1819
84. Cho L, Rocco M, Colquhoun D, et al. Design and rationale of the GAUSS-2 study trial: a double-blind, ezetimibe-controlled phase 3 study of the efficacy and tolerability of evolocumab (AMG 145) in subjects with hypercholesterolemia who are intolerant of statin therapy. Clin Cardiol. 2014 ; 37 (3). 131-139
85. Robinson JG, Rogers WJ, Nedergaard BS, et al. Rationale and design of LAPLACE-2: a phase 3, randomized, double-blind, placebo- and ezetimibe-controlled trial evaluating the efficacy and safety of evolocumab in subjects with hypercholesterolemia on background statin therapy. Clin Cardiol. 2014 ; 37 (4). 195-203
86. Amgen. Trial evaluating PCSK9 antibody in subjects with LDL receptor abnormalities (TESLA). http://clinicaltrials.gov/ct2/show/NCT01588496. Accessed September 12, 2013.
87. Amgen. Further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk (FOURIER). http://clinicaltrials.gov/ct2/show/NCT01764633. Accessed September 12, 2013.
88. Amgen. GLAGOV (global assessment of plaque regression with a PCSK9 antibody as measured by intravascular ultrasound). http://clinicaltrials.gov/show/NCT01813422. Accessed March 2014.
89. Sanofi. Evaluation of cardiovascular outcomes after an acute coronary syndrome during treatment with alirocumab SAR236553 (REGN727) (ODYSSEY outcomes). http://clinicaltrials.gov/ct2/show/NCT01663402. Accessed September 12, 2013.
90. Ballantyne C, Neutel J, et al. Efficacy and safety of bococizumab (RN316/PF-04950615), a monoclonal antibody against proprotein convertase subtilisin/kexin type 9 in statin-treated hypercholesterolemic subjects: results from a randomized, placebo-controlled, dose-ranging study (NCT: 01592240). Poster presented at: American College of Cardiology 63rd Annual Scientific Session and Expo ; Washington, DC ;..
91. Shan L, Pang L, Zhang R, Murgolo NJ, Lan H, Hedrick JA. PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide. Biochem Biophys Res Commun. 2008 ; 375 (1). 69-73
92. Lambert G, Sjouke B, Choque B, Kastelein JJ, Hovingh GK. The PCSK9 decade. J Lipid Res. 2012 ; 53 (12). 2515-2524
93. Lipovsek D. Adnectins: engineered target-binding protein therapeutics. Protein Eng Des Sel. 2011 ; 24 (1-2). 3-9
94. Davidson BL, McCray PB. Current prospects for RNA interference-based therapies. Nat Rev Genet. 2011 ; 12 (5). 329-340
95. Boggs RT, Dean NM. Nucleic acid sequences encoding protein kinase C and antisense inhibition of expression thereof. ; ;..
96. Besseling J, Hovingh GK, Stroes ES. Antisense oligonucleotides in the treatment of lipid disorders: pitfalls and promises. Neth J Med. 2013 ; 71 (3). 118-122
97. Grunweller A, Hartmann RK. Locked nucleic acid oligonucleotides: the next generation of antisense agents?. Biodrugs. 2007 ; 21 (4). 235-243
98. Brautbar A, Ballantyne CM. Pharmacological strategies for lowering LDL cholesterol: statins and beyond. Nat Rev Cardiol. 2011 ; 8 (5). 253-265
99. Gupta N, Fisker N, Asselin MC, et al. A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo. PLoS One. 2010 ; 5 (5). e10682
100. Graham MJ, Lemonidis KM, Whipple CP, et al. Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice. J Lipid Res. 2007 ; 48 (4). 763-767
101. Davignon J, Dubuc G, Seidah NG. The influence of PCSK9 polymorphisms on serum low-density lipoprotein cholesterol and risk of atherosclerosis. Curr Atheroscler Rep. 2010 ; 12 (5). 308-315
102. Lindholm MW, Elmén J, Fisker N, et al. PCSK9 LNA antisense oligonucleotides induce sustained reduction of LDL cholesterol in nonhuman primates. Mol Ther. 2012 ; 20 (2). 376-381
103. Multiple ascending dose study of SPC5001 in treatment of healthy subjects and subjects with FH. ClinicalTrials.gov Identifier: NCT01350960. Last verified November 2011. http://clinicaltrials.gov/show/NCT01350960. Accessed May 21, 2014.
104. Frank-Kamenetsky M, Grefhorst A, Anderson NN, Racie TS, et al. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc Natl Acad Sci USA. 2008 ; 105 (33). 11915-11920
105. Fitzgerald K, Frank-Kamenetsky M, Shulga-Morskaya S, et al. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial. Lancet. 2014 ; 383 (9911). 60-68
106. Luna Saavedra YG, Zhang J, Seidah NG. PCSK9 prosegment chimera as novel inhibitors of LDLR degradation. PLoS One. 2013 ; 8 (8). e72113
107. Banach M, Serban C, Aronow WS, et al. Lipid, blood pressure and kidney update 2013. Int Urol Nephrol. 2014 ; 46 (5). 947-961
108. Franczyk-Skóra B, Gluba A, Banach M, Rysz J. Treatment of non-ST-elevation myocardial infarction and ST-elevation myocardial infarction in patients with chronic kidney disease. Arch Med Sci. 2013 ; 9 (6). 1019-1027